Henry Schein, Inc.
HSICHenry Schein is a leading distributor of medical, dental, and veterinary supplies and equipment.
It operates as a vital intermediary, connecting manufacturers with healthcare providers through its extensive global distribution network.
Updated: February 16, 2026, 16:00 EST
Investment Opinion: Should I buy HSIC Today?
Analysis of Henry Schein (HSIC)
Technical Analysis HSIC has demonstrated strong recent momentum, posting gains of 2. The stock is positioned near the higher end of its 52-week range, signaling potential overbought conditions but confirming strong bullish sentiment. Given the consistent outperformance versus the broader market, momentum appears sustainable in the near term.
Fundamental Analysis HSIC shows modest operational improvement with sequential revenue growth and slightly expanded net margins, though profitability remains thin. The balance sheet carries moderate leverage, but weak cash flow ratios highlight liquidity constraints that could limit financial flexibility. Operational efficiency metrics are underwhelming, with low returns on equity and assets indicating room for improvement in capital allocation.
Valuation & Risk Assessment Valuation appears moderate, with a PEG ratio near 1.0 suggesting the stock is fairly priced relative to its growth outlook. The beta below 1 implies lower volatility than the market, though the significant maximum drawdown underscores meaningful downside risk. Limited short interest reflects stable market sentiment and adequate liquidity.
Recommendation HSIC presents a balanced profile with solid price momentum and reasonable valuation, offset by mediocre fundamentals and liquidity concerns. For investors seeking exposure to the healthcare distribution sector, it represents a fair opportunity with moderate growth potential. Caution is warranted due to weak cash flow coverage and operational inefficiencies, but the stock may suit investors comfortable with its risk-reward profile.
*Note: This is not investment advice, for reference only.*
HSIC 12-Month Price Forecast
RockFlow Model Forecast: Three Scenarios for 2026
Based on the comprehensive analysis, here is a 12-month outlook for Henry Schein (HSIC):
12-Month Outlook for HSIC
The primary catalyst for HSIC over the next year is the continuation of its strong price momentum, which appears sustainable in the near term and is supported by a reasonable valuation. However, this is offset by significant risks stemming from weak cash flow generation, which creates liquidity constraints, and underwhelming operational efficiency that limits fundamental upside. Given the balanced but unexceptional profile with no specific analyst target price available, a cautious outlook is warranted; the stock is likely to track modestly with the broader healthcare sector, with a target range reflecting single-digit percentage movement from the current price, heavily dependent on improved execution.
Wall Street Consensus
Most Wall Street analysts are optimistic about Henry Schein, Inc.'s 12-month outlook, with consensus target around $78.19, indicating expected upside potential.
Bulls vs Bears: HSIC Investment Factors
Overall, HSIC has investment potential but also faces challenges. Here are key factors to weigh before investing.
Bullish
- Barclays Initiation Coverage: Barclays initiated coverage on Henry Schein, driving stock price up nearly 3%.
- AI-Powered Dental Workflows Launch: Henry Schein One rolled out new AI dental workflows boosting growth momentum.
- Expanded vVARDIS Partnership: Exclusive U.S. rights to Curodont from 2026 expected to rebound Dental business.
- Strategic Partnership with KKR: Extended partnership with KKR provides strategic financial backing and operational support.
- Strong Quarterly Sales Beat: Quarterly sales of $12.475 million significantly exceeded analyst consensus estimates.
Bearish
- CEO Transition Impact: Recent CEO change introduces uncertainty and potential disruption to company strategy.
- Moderate Buy Rating Outlook: Analyst ratings show only moderate buy sentiment suggesting limited upside potential.
- High Volatility Concerns: Stock identified as potentially keeping investors 'up at night' indicating risk.
- Industry Competitive Pressure: Wholesale medical equipment sector faces intense competition and margin pressures.
HSIC Technical Analysis
HSIC has exhibited strong price momentum, gaining 2.53% over the past month and 7.11% over three months while significantly outperforming the broad market by 7.06%.
Over the one-month and three-month periods, the stock has delivered solid absolute gains while steadily outpacing the market. Currently priced closer to its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of its price range of ITS price range of ITS price range of ITS price range of ITS price range of ITS price range ! You are a professional stock technical analyst. Please analyze the stock's price performance in three paragraphs: -&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&-&- You are a professional stock technical analyst. Please analyze the stock's price performance in three paragraphs: 1. Overall Assessment (1 paragraph): Summarize overall performance in one sentence 2. Short-term Performance (1 paragraph): Analyze 1-month and 3-month changes, compare with market benchmark 3. Current Position (1 paragraph): Analyze current price position within 52-week range, determine if overbought/oversold
Keep it concise and professional, 2-3 sentences per paragraph.
| Period | HSIC Return | S&P 500 |
|---|---|---|
| 1m | +2.5% | -1.2% |
| 3m | +7.1% | +0.1% |
| 6m | +18.6% | +7.8% |
| 1y | +0.7% | +11.5% |
| ytd | +1.8% | -0.2% |
HSIC Fundamental Analysis
Revenue & Profitability HSIC demonstrated sequential revenue growth from $3.24B in Q2 to $3.34B in Q3, though gross margin dipped slightly from 29.4% to 28.7%. Net income improved to $101M with a net margin of 3.0%, reflecting modest profitability expansion compared to the prior quarter’s 2.7% margin.
Financial Health The company maintains a moderate debt level with a debt-to-equity ratio of 1.02 and interest coverage of 5.4x. However, weak cash ratios and a cash flow-to-debt ratio of just 0.05 indicate limited liquidity and constrained ability to service obligations from operating cash flows.
Operational Efficiency HSIC’s operational performance remains subdued, with low returns on equity (3.0%) and assets (0.9%) reflecting inefficient capital utilization. Asset turnover of 0.30 suggests sluggish revenue generation relative to its asset base, while inventory turnover of 1.25 points to slower-moving stock.
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
RockFlow Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
Try Now & Get Tesla Stock RewardValuation Analysis: Is HSIC Overvalued?
HSIC's valuation appears moderately elevated based on traditional metrics. The TTM PE of 22.34 and forward PE of 19.7 suggest the market is pricing in steady near-term growth expectations, while the EV/EBITDA of 44.1 indicates significant premium relative to operating earnings power. However, the PEG ratio of approximately 1.07 is near the theoretical fair value threshold of 1.0, suggesting the current earnings multiple may be largely justified by the company's estimated growth trajectory.
A peer comparison cannot be concretely assessed without industry benchmarks. The absence of comparative data prevents determining whether HSIC's valuation multiples represent a premium or discount to its sector. Further analysis would require specific industry average ratios for medical distributors or healthcare suppliers to contextualize these valuation levels appropriately.
Investment Risk Disclosure
Volatility Risk: With a beta coefficient of 0.893, HSIC demonstrates moderately lower volatility than the broader market, suggesting it is somewhat less sensitive to market swings. However, the one-year maximum drawdown of -20.53% indicates the stock has experienced significant price declines from recent peaks. This drawdown is substantial, suggesting investors should be prepared for notable downside risk despite the lower-beta profile.
Other Risks: The absence of any reported short interest suggests limited active pessimism or speculative betting against the stock, which can be viewed favorably. From a liquidity standpoint, this lack of short interest, combined with the stock's established market presence, generally indicates good trading liquidity and lower risk of a short squeeze event.
FAQs
Based on the analysis presented, I maintain a neutral view on HSIC.
The stock shows positive technical momentum and strategic growth catalysts from AI dental products and partnerships, but faces headwinds from modest profitability, elevated valuation multiples, and leadership transition risks.
This positioning may suit medium-term investors comfortable with healthcare sector exposure, though both growth and value investors might find more compelling opportunities elsewhere given the mixed signals across technical, fundamental, and valuation factors.
HSIC appears fairly valued to slightly overvalued. The PEG ratio of 1.07 near the theoretical fair value of 1.0 suggests its P/E ratio of 22.34 is largely justified by its growth expectations. However, weak metrics like a low 3.0% ROE and cash flow-to-debt ratio of 0.05 indicate poor profitability and financial health that don't fully support premium valuation. Compared to typical distribution companies, its elevated EV/EBITDA of 44.1 suggests some overvaluation relative to operating earnings power despite the reasonable PEG ratio.
Based on the provided information, here are the key risks of holding HSIC:
1. Financial Risk: Weak cash flow coverage (cash flow-to-debt ratio of 0.05) severely constrains the company's ability to service its obligations from operating activities. 2. Operational Risk: Subdued operational efficiency, with low returns on equity (3.0%) and assets (0.9%), reflects poor capital utilization. 3. Market Risk: Despite having a relatively low beta coefficient (0.893), the stock has exhibited significant downside volatility, evidenced by a maximum drawdown of -20.53% over the past year. 4. Business Risk: Sluggish asset turnover (0.30) and inventory turnover (1.25) suggest lackluster revenue generation relative to its asset base and slow-moving stock management.
Based on the provided analysis, my forecast for Henry Schein (HSIC) through 2026 is for subdued growth, with a base case target range of $80-$85 and a bull case of up to $95, contingent on significant operational improvements.
Key growth drivers include the potential for margin expansion from improved operational efficiency and sustained revenue momentum from its essential healthcare distribution role, though both are currently weak spots. My main assumptions are that the company's moderate debt remains manageable and that management executes on improving cash flow and asset utilization.
This forecast carries high uncertainty, heavily dependent on reversing the current trends of weak cash flow and low operational returns; without meaningful improvement, the stock could stagnate or underperform the broader market.